• Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Life Sciences British Columbia

  • Newsletters |
  • Members Area |
  • Contact
  • SearchSearch
  • About
    • Board of Directors
    • Management
    • Vision & Mission
  • Awards
  • Membership
    • Sponsors
    • Members Directory
    • Members Area
    • Membership Benefits
    • Membership Discounts
    • Members Services
    • Members Map
    • Become a Member
  • Events
    • Calendar
    • Webinars
    • Past Events
      • 2023 Events
      • 2022 Events
      • 2021 Events
      • 2020 Events
      • 2019 Events
      • 2018 Events
  • News
    • All News
    • Member News
    • Industry News
    • LSBC in The News
    • Publications
    • BC Labour Market Study
  • Resources
    • All Resources
    • Grants and Funding
      • Funding Competitions
      • Wage Subsidies
    • Academic Institutions
    • Government
      • Federal
      • Provincial and Municipal
    • Association Partners
    • Programs
    • Volunteering
  • Jobs
    • Job Board
    • Post a Job
    • Career Events
  • Contact Us
  • Login
Home » All News » PharmAust successfully reformulates cancer drug

All News

  • Member News
  • Industry News
  • LSBC in The News
Member News

PharmAust successfully reformulates cancer drug

April 3, 2019
LSBC Comms

April 3, 2019 – ASX-listed biotech PharmAust, has successfully managed to reformulate its potentially breakthrough cancer drug Monepantel after feedback from previous trials that the taste was unpalatable.

The reformulation has now cleared the way for new canine clinical trials, a key milestone along the company’s drug development journey that is looking increasingly exciting.

In a recent market update, the Perth-based company said it has successfully revamped Monepantel’s formulation to improve the drugs’s taste and meeting the company’s dosage requirements.

The overhauled formulation takes the form of a dry tablet composed of “micromized” monepantel , which will be further optimized and refined during canine clinical trials.

If the canine trial, slated for Q4/2018 meets expectations, the company then plans to undertake a human clinical trial.

PharmaAust Executive Chairman Dr. Roger Aston said: “We are pleased the BRI collaboration has identified a new tablet-based formulation that clears the path for us to re-initiate clinical trials in late 2018. These efforts will focus initially in dogs before moving into human clinical trials.”

PharmaAust hit the major company milestone after partnering with Canadian-based BRI Biopharmaceutical Research, who has assisted it to successfully identify the reformulation approach. The collaboration, initiated last year, revealed micronization of Monepantel, a highly technical milling technique, as the best way to meet PharmAust’s requirements for dosing, taste-masking and oral bioavailability.

Primary Sidebar

  • Category:

  • Sector:

  • Archives:

© 2023 Life Sciences BC  |  Privacy Policy

  • Current Jobs
  • Event Calendar
  • All News
  • Member Directory
    Connect with us
  • LinkedIn
  • Twitter
  • Facebook
  • Instagram
Contact Us